Skip to main content

letter

. 1996 Dec 14;313(7071):1553–1554. doi: 10.1136/bmj.313.7071.1553a

Adverse events associated with mefloquine. Risk-benefit ratio must be taken into account.

PMCID: PMC2353025 PMID: 8978258

1553

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Barrett P. J., Emmins P. D., Clarke P. D., Bradley D. J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ. 1996 Aug 31;313(7056):525–528. doi: 10.1136/bmj.313.7056.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
Croft A. M., World M. J. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet. 1996 Feb 3;347(8997):326–326. doi: 10.1016/s0140-6736(96)90500-0. [DOI] [PubMed] [Google Scholar]
Lobel H. O., Miani M., Eng T., Bernard K. W., Hightower A. W., Campbell C. C. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 1993 Apr 3;341(8849):848–851. doi: 10.1016/0140-6736(93)93058-9. [DOI] [PubMed] [Google Scholar]
Steffen R., Fuchs E., Schildknecht J., Naef U., Funk M., Schlagenhauf P., Phillips-Howard P., Nevill C., Stürchler D. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet. 1993 May 22;341(8856):1299–1303. doi: 10.1016/0140-6736(93)90814-w. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES